Abstract B52: KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

作者
Wenting Liao,Michael James Overman,Adam T. Boutin,Scott Kopetz,Ronald Anthony DePinho,Alan Wang
出处
期刊:Molecular Cancer Research [American Association for Cancer Research]
卷期号:18 (5_Supplement): B52-B52 被引量:1
标识
DOI:10.1158/1557-3125.ras18-b52
摘要

Abstract The precise biologic functions and mechanisms of oncogenic KrasG12D (Kras*) in therapeutic resistance, including immune therapy, are not understood. Here, utilizing a colorectal cancer (CRC) mouse model engineered with an inducible Kras* transgene and conditional null APC and Trp53 alleles (iKAP) that we recently established (Boutin et al., Gene & Development 2017), we observed that KRAS*-expressing invasive tumors possess a prominent immune-suppressive profile characterized by a preponderance of myeloid-derived suppressor cells (MDSCs). Integrated transcriptomic and genomic analyses identified the Interferon Regulatory Factor 2 (IRF2) gene as a key downstream target of KRAS* mediating tumor progression and immune suppression. Mechanistically, integrated transcriptomics, cytokine profiling and ChIP-seq analysis identified CXCL3 as a key direct target of IRF2, and pharmacologic inhibition of CXCL3 or its receptor CXCR2 resulted in suppression of MDSC migration and infiltration in KRAS*-expressing CRC tumors. Translational studies established that de novo anti-PD1 resistance of KRAS*-expressing tumors can be overcome by enforced IRF2 expression or by treatment with small-molecule CXCR2 antagonist SX-682. Correspondingly, CRC patient tumors with higher IRF2 expression show increased response to anti-PD1 therapy. This KRAS*-mediated immune suppressive mechanism provides a framework for patient selection and combination therapies to enhance the effectiveness of immune checkpoint blockade therapy in advanced CRC. Citation Format: Wenting Liao, Michael Overman, Adam Boutin, Scott Kopetz, Ron DePinho, Alan Wang. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr B52.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎的应助被西瓜皮采纳,获得10
刚刚
彩色的朋发布了新的文献求助10
1秒前
1秒前
传奇3的应助被pp009900采纳,获得10
1秒前
1秒前
大胆绿柳发布了新的文献求助10
1秒前
hanli发布了新的文献求助10
2秒前
2秒前
大雪纷飞发布了新的文献求助10
2秒前
2秒前
hahaha发布了新的文献求助30
2秒前
yoshi发布了新的文献求助10
3秒前
领导范儿的应助被酷酷柚子采纳,获得10
3秒前
3秒前
深情安青的应助被五五Rcwt采纳,获得10
3秒前
东方欲晓发布了新的文献求助30
3秒前
3秒前
4秒前
共享精神的应助被顺利汉堡采纳,获得30
4秒前
5秒前
6秒前
Hello的应助被Ceylon采纳,获得10
6秒前
变形金刚发布了新的文献求助10
6秒前
7秒前
msk发布了新的文献求助10
7秒前
细腻的渊思完成签到 ,获得积分20
7秒前
7秒前
高高冷风发布了新的文献求助10
7秒前
科研通AI6.3的应助被dzx采纳,获得10
7秒前
一口三明治完成签到,获得积分10
7秒前
LJHUA完成签到,获得积分10
8秒前
ding的应助被111采纳,获得10
8秒前
chiyudawang发布了新的文献求助50
8秒前
9秒前
天天快乐的应助被2025210129采纳,获得10
9秒前
9秒前
9秒前
aiming完成签到,获得积分10
9秒前
CipherSage的应助被纯真的青雪采纳,获得10
9秒前
CipherSage的应助被hanli采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178341
求助须知:如何正确求助?哪些是违规求助? 9569073
关于积分的说明 21802629
捐赠科研通 7773188
什么是DOI,文献DOI怎么找? 3432780
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478298